Omnicell Keeps $425 Million To $560 Million Bookings Range, Says Deal Timing Is The Swing

The CFO said late-year deal timing makes full-year product bookings hard to narrow, even as the company raised profit guidance.

Share
Omnicell Keeps $425 Million To $560 Million Bookings Range, Says Deal Timing Is The Swing

Omnicell, which makes the medication management systems hospitals and pharmacies use to store, dispense and track drugs, left its full-year 2026 product bookings range unchanged at $425 million to $560 million. Chief Financial Officer Baird Radford told analysts on the company's Thursday third-quarter earnings call that deal timing, not demand, keeps the range wide.

Why the range stays wide

Radford said bookings are weighted toward the end of the year, and that the timing of a number of medium and large deals makes bookings that close before December 31 "a bit hard to project within a narrow range" this early in the product refresh cycle. The low end remains $425 million, and he said the risks and opportunities have not changed since the second-quarter call.

He pointed to two forces. Competitive deals are binary, he said, and management anticipates "winning some and losing some." On timing, health systems decide "based on their timelines and needs, not ours."

A Wells Fargo analyst asked what gets the company to the high or low end, and whether the roughly $135 million gap between the ends would fall into 2027 if the low end is hit. Neither Radford nor President and Chief Operating Officer Nnamdi Njoku addressed the 2027 point directly.

A softer fourth-quarter product outlook

A KeyBanc analyst noted that fourth-quarter product revenue guidance is slightly down, about $10 million at the midpoint from last quarter. Radford confirmed a sequential decline and said it comes from no single customer or competitive dynamic. With two months left in the year, he said, scheduling visibility lets the company narrow the range. He added that the fourth-quarter guide implies full-year results still inside the original range, at the lower end.

Part of the decline, though "not the lion's share," reflects back-end bookings converting to revenue within the year less than they historically have, Radford said. Njoku said competitive wins take nine to 12 months to turn into revenue, so those would show up in the back half of next year.

For the fourth quarter, Omnicell guided total revenue of $295 million to $301 million and adjusted EBITDA of $30 million to $36 million. It raised full-year adjusted EBITDA and earnings-per-share guidance and narrowed its revenue ranges, with full-year revenue at $1.225 billion to $1.231 billion.

Strong quarter, early refresh cycle

Third-quarter revenue was $308 million, above the company's $301 million to $307 million guidance, and adjusted EBITDA was $45 million against guidance of $32 million to $37 million. Adjusted earnings per share were $0.58, and the company ended the quarter with $315 million in cash.

Omnicell is early in a hardware refresh built around Titan XT cabinets and the cloud platform Omnisphere. Njoku said the first Titan XT shipment is days away and Omnisphere general availability is targeted for the first half of 2027. Radford said the older XT install base is younger than the prior generation was at the same point in the last cycle, which may create near-term pacing considerations for bookings.

Radford said the total replacement opportunity exceeds $2.5 billion. That figure is hardware only and based on the installed base alone, so it excludes market-share gains and Omnisphere revenue, he said.

The next test is the fourth quarter, when Omnicell will find out where full-year product bookings land within its $425 million to $560 million range.

Sources

More on Omnicell

All Omnicell (OMCL) coverage →